FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2771040050> ?p ?o ?g. }

• W2771040050 endingPage "811" @default.
• W2771040050 startingPage "802" @default.
• W2771040050 abstract "// Xinwei Kuang 1, 2 , Min Qi 3 , Cong Peng 1, 2 , Chengfang Zhou 4 , Juan Su 1, 2 , Weiqi Zeng 1, 2 , Hong Liu 1, 2 , Jianglin Zhang 1, 2 , Mingliang Chen 1, 2 , Minxue Shen 1, 2 , Xiaoyun Xie 5 , Fangfang Li 1, 2 , Shuang Zhao 1, 2 , Qingling Li 6 , Zhongling Luo 1, 2 , Junchen Chen 1, 2 , Juan Tao 7 , Yijing He 1, 2 and Xiang Chen 1, 2 1 Department of Dermatology, XiangYa Hospital, Central South University, Changsha, China 2 Hunan Key Laboratory of Skin Cancer and Psoriasis, Changsha, China 3 Department of Plastic and Cosmetic Surgery, XiangYa Hospital, Central South University, Changsha, China 4 Department of Clinical Pharmacology, XiangYa Hospital, Central South University, Changsha, China 5 Department of Rheumatology, XiangYa Hospital, Central South University, Changsha, China 6 Department of Pathology, XiangYa Hospital, Central South University, Changsha, China 7 Department of Dermatology, Affiliated Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China Correspondence to: Xiang Chen, email: chenxiangck@126.com Yijing He, email: yijing.he@foxmail.com Keywords: malignant melanoma; sunitinib; propranolol; combination treatment; cell cycle Received: August 24, 2017      Accepted: September 21, 2017      Published: November 25, 2017 ABSTRACT Both sunitinib, a multi-target tyrosine kinase inhibitor (TKI) and propranolol, a non-selective β-blocker, have proven therapeutic effects on malignant melanoma (MM). This study reports a synergistic effect of propranolol and sunitinib upon A375, P8 MM cell lines and mice xenografts. Cell viability assays detected a significant decrease of sunitinib IC50 in combination with propranolol, which was confirmed by a colony formation assay. Western blot showed that propranolol and sunitinib combination significantly down-regulated phospho-Rb, phospho-ERK, Cyclin D1, and Cyclin E, but had no effect on Bax, Bcl-2, or cleaved PARP expression. The average tumor size of propranolol and low-dose sunitinib (Sun L) combination treated mice was reduced and similar to high-dose sunitinib treated A375 xenografts. The Ki67 index was significantly reduced in propranolol and Sun L combination treated group compared with single Sun L treated group. This synergistic effect between propranolol and sunitinib to inhibit MM proliferation was through suppressing ERK/Cyclin D1/Rb/Cyclin E pathways and inducing G0/G1/S phase arrest, rather than by inducing tumor cell apoptosis." @default.
• W2771040050 created "2017-12-04" @default.
• W2771040050 creator A5023743448 @default.
• W2771040050 creator A5031061480 @default.
• W2771040050 creator A5035699180 @default.
• W2771040050 creator A5036994170 @default.
• W2771040050 creator A5038302775 @default.
• W2771040050 creator A5040219665 @default.
• W2771040050 creator A5052226982 @default.
• W2771040050 creator A5054012489 @default.
• W2771040050 creator A5056986109 @default.
• W2771040050 creator A5057193330 @default.
• W2771040050 creator A5057287134 @default.
• W2771040050 creator A5060801050 @default.
• W2771040050 creator A5062361716 @default.
• W2771040050 creator A5064454449 @default.
• W2771040050 creator A5068144237 @default.
• W2771040050 creator A5069521470 @default.
• W2771040050 creator A5074511281 @default.
• W2771040050 creator A5075215313 @default.
• W2771040050 creator A5076768386 @default.
• W2771040050 date "2017-11-25" @default.
• W2771040050 modified "2023-10-05" @default.
• W2771040050 title "Propranolol enhanced the anti-tumor effect of sunitinib by inhibiting proliferation and inducing G0/G1/S phase arrest in malignant melanoma" @default.
• W2771040050 cites W1509291382 @default.
• W2771040050 cites W1743944563 @default.
• W2771040050 cites W1891422611 @default.
• W2771040050 cites W1963910752 @default.
• W2771040050 cites W1975045288 @default.
• W2771040050 cites W2026683311 @default.
• W2771040050 cites W2060224273 @default.
• W2771040050 cites W2061708568 @default.
• W2771040050 cites W2077700022 @default.
• W2771040050 cites W2077939167 @default.
• W2771040050 cites W2080347660 @default.
• W2771040050 cites W2086796040 @default.
• W2771040050 cites W2100584705 @default.
• W2771040050 cites W2102717686 @default.
• W2771040050 cites W2108808854 @default.
• W2771040050 cites W2112468133 @default.
• W2771040050 cites W2132750237 @default.
• W2771040050 cites W2138150045 @default.
• W2771040050 cites W2139731996 @default.
• W2771040050 cites W2141258748 @default.
• W2771040050 cites W2147055430 @default.
• W2771040050 cites W2147482894 @default.
• W2771040050 cites W2149487627 @default.
• W2771040050 cites W2150740158 @default.
• W2771040050 cites W2158189520 @default.
• W2771040050 cites W2159422800 @default.
• W2771040050 cites W2163473856 @default.
• W2771040050 cites W2170674837 @default.
• W2771040050 cites W2171415105 @default.
• W2771040050 cites W2208837625 @default.
• W2771040050 cites W2264733982 @default.
• W2771040050 cites W2286357201 @default.
• W2771040050 cites W2465307893 @default.
• W2771040050 cites W2514175877 @default.
• W2771040050 cites W2549731793 @default.
• W2771040050 cites W2559365457 @default.
• W2771040050 cites W2560646828 @default.
• W2771040050 cites W2677507591 @default.
• W2771040050 cites W2735639179 @default.
• W2771040050 doi "https://doi.org/10.18632/oncotarget.22696" @default.
• W2771040050 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5787512" @default.
• W2771040050 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29416656" @default.
• W2771040050 hasPublicationYear "2017" @default.
• W2771040050 type Work @default.
• W2771040050 sameAs 2771040050 @default.
• W2771040050 citedByCount "17" @default.
• W2771040050 countsByYear W27710400502018 @default.
• W2771040050 countsByYear W27710400502019 @default.
• W2771040050 countsByYear W27710400502020 @default.
• W2771040050 countsByYear W27710400502021 @default.
• W2771040050 countsByYear W27710400502022 @default.
• W2771040050 countsByYear W27710400502023 @default.
• W2771040050 crossrefType "journal-article" @default.
• W2771040050 hasAuthorship W2771040050A5023743448 @default.
• W2771040050 hasAuthorship W2771040050A5031061480 @default.
• W2771040050 hasAuthorship W2771040050A5035699180 @default.
• W2771040050 hasAuthorship W2771040050A5036994170 @default.
• W2771040050 hasAuthorship W2771040050A5038302775 @default.
• W2771040050 hasAuthorship W2771040050A5040219665 @default.
• W2771040050 hasAuthorship W2771040050A5052226982 @default.
• W2771040050 hasAuthorship W2771040050A5054012489 @default.
• W2771040050 hasAuthorship W2771040050A5056986109 @default.
• W2771040050 hasAuthorship W2771040050A5057193330 @default.
• W2771040050 hasAuthorship W2771040050A5057287134 @default.
• W2771040050 hasAuthorship W2771040050A5060801050 @default.
• W2771040050 hasAuthorship W2771040050A5062361716 @default.
• W2771040050 hasAuthorship W2771040050A5064454449 @default.
• W2771040050 hasAuthorship W2771040050A5068144237 @default.
• W2771040050 hasAuthorship W2771040050A5069521470 @default.
• W2771040050 hasAuthorship W2771040050A5074511281 @default.
• W2771040050 hasAuthorship W2771040050A5075215313 @default.
• W2771040050 hasAuthorship W2771040050A5076768386 @default.
• W2771040050 hasBestOaLocation W27710400501 @default.
• W2771040050 hasConcept C121608353 @default.

• next